Previous 10 | Next 10 |
Epic Sciences is collaborating with Fulgent Genetics (FLGT -5.9%) to deliver DefineMBC profiling results for patients with metastatic breast cancer (MBC). The partnership links Fulgent's CAP/CLIA certified next generation sequencing services with Epic's cell analysis platform as part of ...
EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS Epic Sciences scales its workflow for ctDNA testing with Next Generation Sequencing Leader Fulgent Fulgent Genetics' expertise in high-volume testing pow...
Image source: The Motley Fool. Fulgent Genetics, Inc. (NASDAQ: FLGT) Q4 2021 Earnings Call Feb 23, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Fulgent Genetics, Inc. (FLGT) Q4 2021 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q4 2021 Earnings Conference Call February 23, 2022 04:30 PM ET Company Participants Nicole Borsje - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Larry Weiss - Chief Medical ...
Shares of Fulgent Genetics (NASDAQ:FLGT) are down 12% in after-hours trading despite quarterly results that beat on the top and bottom lines. Net income fell 37% to ~104.3M compared to the prior-year period. Diluted earnings per share went from $6.16 to $3.34. Net revenue in the qua...
The following slide deck was published by Fulgent Genetics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Fulgent Genetics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Fulgent Genetics (NASDAQ:FLGT) announced a strategic investment in Spatial Genomics, a developer of sequential fluorescence in situ hybridization (seqFISH) technology. FLGT is investing up to $40M to lead Spatial's series A financing, which totals ~$56M and also includes investments by 12 Wes...
Fulgent Genetics press release (NASDAQ:FLGT): Q4 Non-GAAP EPS of $3.48 beats by $0.81. Revenue of $251.7M beats by $60.6M. Shares -5%. Outlook Q1 2022:T otal Revenue of approximately $245 million; Core Revenue including COVID-19 NGS of approximately $32 million, representing growth ...
Strategic investment and partnership brings Spatial’s multiomics platform and seqFISH technology to Fulgent’s comprehensive suite of genomic testing solutions Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a tech...
Full Year 2021 Total Revenue grows 135% year-over-year to $992.6 million; Q4 Revenue totals $251.7 million Full Year 2021 Core Revenue grows 236% year-over-year to $122.6 million; Q4 Core Revenue grows 234% year-over-year to $40.1 million Fulgent Genetics, Inc. (NASDAQ: ...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...
2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...